Business
A New Biotech Wants to “Reset” Autoimmune Disease by Deleting the T Cells That Drive It
ai3Bio, formed from two startups and backed with $48 million, is developing an mRNA treatment that tells inflammatory Th17 cells to self-destruct. It is early — animal data only — but it targets a different culprit from most “immune reset” efforts.